Genetic ablation of soluble TNF does not affect lesion size and functional recovery after moderate spinal cord injury in mice by Ellman, Ditte Gry et al.
Syddansk Universitet
Genetic ablation of soluble TNF does not affect lesion size and functional recovery
after moderate spinal cord injury in mice
Ellman, Ditte Gry; Degn, Matilda; Lund, Minna Christiansen; Clausen, Bettina Hjelm; Novrup,
Hans Gram ; Flæng, Simon Bertram; Jørgensen, Louise Helskov; Suntharalingam, Lujitha;
Fex Svenningsen, Åsa; Brambilla, Roberta; Lambertsen, Kate Lykke
Published in:
Mediators of Inflammation
DOI:
10.1155/2016/2684098
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Ellman, D. G., Degn, M., Lund, M. C., Clausen, B. H., Novrup, H. G., Flæng, S. B., ... Lambertsen, K. L. (2016).
Genetic ablation of soluble TNF does not affect lesion size and functional recovery after moderate spinal cord
injury in mice. Mediators of Inflammation, 2016, [2684098]. DOI: 10.1155/2016/2684098
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Research Article
Genetic Ablation of Soluble TNF Does Not Affect Lesion Size and
Functional Recovery after Moderate Spinal Cord Injury in Mice
Ditte Gry Ellman,1 Matilda Degn,2 Minna Christiansen Lund,1
Bettina Hjelm Clausen,1 Hans GramNovrup,1 Simon Bertram Flæng,1
Louise Helskov Jørgensen,3 Lujitha Suntharalingam,1 Åsa Fex Svenningsen,1
Roberta Brambilla,4 and Kate Lykke Lambertsen1,5,6
1Neurobiology Research, Institute of Molecular Medicine, J.B. Winsloewsvej 21, st, 5000 Odense C, Denmark
2Department of Diagnostics, Molecular Sleep Lab, Rigshospitalet, Nordre Ringvej 69, 2600 Glostrup, Denmark
3Department of Pathology, Department of Clinical Research, SDU Muscle Research Cluster, University of Southern Denmark,
J.B. Winsloewsvej 15, 5000 Odense C, Denmark
4The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, 1095 NW 14th Terrace, Miami, FL 33136, USA
5Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense C, Denmark
6Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, 5000 Odense C, Denmark
Correspondence should be addressed to Kate Lykke Lambertsen; klambertsen@health.sdu.dk
Received 8 August 2016; Revised 24 October 2016; Accepted 3 November 2016
Academic Editor: Ana Raquel Santiago
Copyright © 2016 Ditte Gry Ellman et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Traumatic spinal cord injury (SCI) is followed by an instant increase in expression of the microglial-derived proinflammatory
cytokine tumor necrosis factor (TNF) within the lesioned cord. TNF exists both as membrane-anchored TNF (mTNF) and as
cleaved soluble TNF (solTNF). We previously demonstrated that epidural administration of a dominant-negative inhibitor of
solTNF, XPro1595, to the contused spinal cord resulted in changes in Iba1 protein expression in microglia/macrophages, decreased
lesion volume, and improved locomotor function. Here, we extend our studies using mice expressing mTNF, but no solTNF
(mTNFΔ/Δ), to study the effect of genetic ablation of solTNF on SCI. We demonstrate that TNF levels were significantly decreased
within the lesioned spinal cord 3 days after SCI in mTNFΔ/Δ mice compared to littermates.This decrease did, however, not translate
into significant changes in other pro- and anti-inflammatory cytokines (IL-10, IL-1𝛽, IL-6, IL-5, IL-2, CXCL1, CCL2, or CCL5),
despite a tendency towards increased IL-10 anddecreased IL-1𝛽, TNFR1, andTNFR2 levels inmTNFΔ/Δmice. In addition,microglial
and leukocyte infiltration, activation state (Iba1, CD11b, CD11c, CD45, and MHCII), lesion size, and functional outcome after
moderate SCI were comparable between genotypes. Collectively, our data demonstrate that genetic ablation of solTNF does not
significantly modulate postlesion outcome after SCI.
1. Introduction
Traumatic spinal cord injury (SCI) is most often caused by
a sudden contusion of the spinal cord, where the initial
tissue damage is followed by a second phase of cell death,
inflammation, and degeneration that occurs over weeks and
months after the initial trauma.
The microglial-derived cytokine tumor necrosis factor
(TNF) increases at the lesion site within the first 1-2 hours
after SCI in rodents [1–4] and spinal cord injured individuals
display elevated TNF serum concentrations [5, 6], suggesting
that TNF plays a major part in the development of secondary
tissue damage [7].
TNF exists in two biologically active forms, a membrane-
anchored form (mTNF) and a soluble form (solTNF), which
is shed from the membrane by the metalloproteinase TNF-𝛼
converting enzyme (TACE/ADAM17). The biological effects
of solTNF and mTNF are mediated through binding of TNF
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receptor 1 (TNFR1) and TNFR2, which differ in expression,
ligand affinity, cytoplasmic tail structure, and downstream
signaling pathways (reviewed in Probert [8]).
In experimental focal cerebral ischemia, an acute CNS
injury, microglial-derived mTNF has been shown to be
neuroprotective through binding to TNFR1 [9–12]. However,
in SCI the data are conflicting. Kim and colleagues found
TNFR1−/− mice to have increased lesion size and worse
functional outcome compared to controls [13], suggesting
a protective role for TNFR1, whereas Genovese et al. [14]
demonstrated reduced tissue damage and improved motor
function in mice treated with the nonselective TNF inhibitor
infliximab as well as in TNFR1−/− mice, indicating a detri-
mental role for TNFR1. Surprisingly, germ-line ablation of
TNF in TNF−/− mice did not result in any differences in
lesion size and functional outcome following SCI compared
to controls [15]. We recently demonstrated that epidural
administration of the dominant-negative solTNF inhibitor
XPro1595 reduced lesion size and improved functional out-
come following SCI, whereas etanercept, inhibitor of both
mTNF and solTNF, had no effect [16]. Importantly, systemic
administration of either compound was ineffective [16], in
line with other studies showing that systemic administra-
tion of etanercept following SCI in mice does not reduce
inflammation and tissue injury or infiltration of neutrophils
nor improves the functional outcome [17]. Late blockage
of peripheral TNF with etanercept was also ineffective in
improving locomotor function inmice with SCI [18], while in
rats it reduced tissue damage, improved hindlimb function,
and facilitated myelin regeneration [19]. It should also be
mentioned that a case report of a spinal cord injured patient
treated chronically with etanercept for ankylosing spondylitis
demonstrated reduced inflammation, reduced perilesional
area, and improved motor recovery [20].
Even though the studies into the role of microglial-
derived TNF following SCI are inconclusive, they clearly
demonstrate that the TNF-TNFR signaling cascade plays
an important part in tissue inflammation, although the
contribution of solTNF versus mTNF to tissue damage and
functional recovery remains to be elucidated. In this study,
we investigated the effect of solTNF and mTNF in SCI using
genetically modified mTNFΔ/Δ mice that express only mTNF
[21]. We show that absence of solTNF in mTNFΔ/Δ mice
does not affect lesion size and functional outcome 35 days
after SCI. However TNF levels are significantly decreased
within the lesioned spinal cord 3 days after SCI compared to
littermate control mice (mTNFwt/wt). These findings suggest
that genetic ablation of solTNF does not affect lesion size and
functional outcome after SCI.
2. Materials and Methods
2.1.Mice. HomozygousmTNFΔ/Δ andmTNFwt/wt littermates
were obtained by crossing heterozygous mTNFΔ/wt mice at
the Biomedical Laboratory, University of Southern Denmark
(SDU) [12, 21]. These mice were originally generated by
replacing the endogenous TNF allele with Δ1–9, K11E TNF
allele [21]. This resulted in loss of TACE-mediated cleavage
preventing shedding of solTNF [21, 22] but maintenance of
normal cell-surface expression ofmTNF [21]. All experiments
were performed blinded on age-matched (8–12 weeks) female
mTNFΔ/Δ and mTNFwt/wt littermates. Animals were housed
in ventilated cages with 1–3 cage-mates at a 12 h light/dark
cycle, under controlled temperature and humidity, and with
free access to food and water.
Mice were cared for in accordance with the protocols
and guidelines approved byThe Danish Animal Inspectorate
under the Ministry of Food and Agriculture (J. numbers
2008-561-1523 and 2013-15-2934-00924); experiments are
reported in accordance with the ARRIVE guidelines, and all
efforts were made to minimize pain and distress.
2.2. Genotyping. DNA was extracted from tail biopsies from
3-4-week-old mice using a NucleoSpin Tissue kit (Macherey-
Nagel) according to the manufacturer’s instructions. DNA
was amplified by PCR under the following conditions: 50∘C
for 2 minutes and 95∘C for 10 minutes followed by 39 cycles
of 95∘C for 15 sec, 62∘C for 1 minute, and 72∘C for 1 minute
and the following per PCR reaction: 12.5 𝜇L Master Mix
(Thermo Scientific), 1 𝜇L forward primer (5󸀠-GCGTCCAGC-
TGACTAAA), 1 𝜇L reverse primer (3󸀠-ACCACTAGTTGG-
TTGCTTTGAGAT), and 10 𝜇L dH2O. Both primers were
from DNA Technology A/S and in working concentrations
of 10 pmol/𝜇L. The PCR products were visualized using
the FlashGel system (Lonza). Four-microliter PCR products
mixed with FlashGel loading buffer (Lonza) were loaded on
FlashGel DNA cassette 1.2% agarose gel with 16 + 1 double
wells (Lonza) and the gels were allowed to run for 25–30
minutes at 70 volts. In all gels, FlashGel system DNA marker
(Lonza) and samples with known genotypes (homozygote,
heterozygote, and wild type) were included.
2.3. Behavioral Analysis. We have previously performed a
thorough behavioral assessment of mTNFΔ/Δ in na¨ıve con-
ditions and found no differences in behavioral phenotype
compared to mTNFwt/wt littermates [12].
Elevated PlusMaze. To further examine anxiety-like behavior
and locomotion, which could affect locomotor function after
SCI, naı¨ve mice were subjected to the elevated plus maze
(EPM). The elevated plus maze apparatus consisted of two
open arms and two closed arms (30 cm × 5 cm). The entire
maze was elevated around 40 cm from the floor. Each mouse
was placed in the center of the maze with the head facing
towards the open arm. During a 5min test, the time spent in
the closed and open arms and the total distance moved were
recorded using the SMART video tracking software (Panlab).
2.4. Contusive Spinal Cord Injury. Mice were anaesthetized
using a ketamine (100mg/kg, VEDCO Inc)/xylazine
(10mg/kg, VEDCO Inc) cocktail, laminectomized between
vertebrae T8 and T10 and injured with an Infinite Horizon-
0400 SCI Contusion Devise (Precision Systems and
Instrumentation, LLC) by lowering the impactor onto
the exposed cord at an impact of 75 Kdynes resulting in
approximately 500𝜇m displacement (moderate injury) [16].
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Mice were then sutured, injected with saline to prevent
dehydration, and given buprenorphine hydrochloride
(0.001mg/20 g body weight Temgesic) four times at 8-hour
intervals for postsurgical analgesia. Mice were housed
separately in a recovery room and monitored for a 24- to 48-
hour recovery period. Thereafter, mice were observed twice
daily for activity level, respiratory rate, and general physical
condition. Manual bladder expression was performed twice
a day until bladder function was regained. Body weight
was monitored weekly. In addition, mice received s.c.
prophylactic injections of antibiotic gentamicin (40mg/kg)
for 7 days to prevent urinary tract infections. The persons
performing the SCI have attended the SCI Research Training
Program at the Ohio State University. In total, 2 mTNFΔ/Δ
mice died during surgery, while 1 mTNFwt/wt and 1 mTNFΔ/Δ
mouse were euthanized on day 8 and day 24, respectively,
due to poor general health status.
2.5. Assessment of Functional Outcome after SCI
BassoMouse Scale. Functional recovery of hind limb function
after SCI was determined by scoring of the locomotor
hindlimb performance in the open field using the Basso
Mouse Scale (BMS) system, a 0 to 9 rating system designed
specifically for the mouse [16, 23]. Under observer-blinded
conditions, mice were evaluated over a 4-min period 1 and
3 days after SCI and weekly thereafter. Only mice with a
score below 2, representing a successful lesion, on day 1 were
included in the study. Before surgery, mice were handled
and pretrained in the open field to prevent fear and/or stress
behaviors that could bias the locomotor assessment.
Thermal Hyperalgesia. Thermal hyperalgesia (hind paw with-
drawal from a normally innocuous heat source) was tested
with a Hargreaves’ heat source using the Plantar Test appara-
tus (Ugo Basile) [16]. Each pawwas tested 5 times with at least
2min break in between.The lowest and highest reflex latency
scores of each paw were discarded and the bilateral mean was
calculated and plotted. The behavioral test was performed
weekly when the mice reached a BMS score of 5 and were
capable of frequent or consistent stepping and thereby plantar
placement of the paws, typically around 3 weeks after SCI.
Rung Walk. In order to test stepping, interlimb coordination,
and balance, mice were tested on the rung walk also when
they reached a BMS score of 5.The rungwalk consisted of two
plates of transparent polymer, approximately 110 cm × 20 cm,
with a 2.5 cm space between them. The apparatus was placed
on two cages with the home cage at one end, making themice
automatically walk in that direction. To avoid stopping or
turning during trials, animals were pretrained 5 times prior to
surgery with the final test serving as baseline. Following SCI,
eligible mice were tested at 3, 4, and 5 weeks using a handheld
GoPro HD camera with 48 fps. Data were evaluated frame by
frame usingQuickTime. Left and right scores were calculated
as follows: 6, complete miss; 5, touching rung but sliding off
and losing balance; 4, touch, miss but no loss of balance; 3,
replacement, mouse placed paw on rung but quickly moves
it; 2, recorrection, aims for a rung but changes direction;
1, anterior or posterior placement; 0, perfect step. The total
number of mistakes was plotted for analysis as previously
described [16].
Open Field Test. The open field test was performed with
a nontransparent squared plastic box (45 × 45 × 45 cm)
over a period of 10min 35 days after SCI [16]. Movements
were tracked using the SMART video tracking software
(Panlab) connected to a video camera (SSC-D378P, Biosite).
The distance travelled (m), speed (cm/sec), and entries into
the three zones (wall, interperiphery, and center of the
box) were recorded automatically. A center/perimeter ratio
was calculated based on the number of entries. Rearing,
grooming, jumping, digging, urination, and droppings were
recorded manually and presented as number (𝑛) of events
[24].
2.6. Tissue Processing
2.6.1. Histopathology and Immunohistochemistry. For paraf-
fin histopathology and immunohistochemical analyses, mice
were deeply anaesthetized using an overdose of pentobarbital
(200mg/mL) containing lidocaine (20mg/mL) and perfused
through the left ventricle with ice-cold 4% paraformaldehyde
(PFA) in phosphate-buffered saline (PBS). The spinal cords
were quickly removed and tissue segments containing the
lesion area (1 cm centered on the lesion) were paraffin-
embedded and cut into 10 parallel series of 15𝜇mthickmicro-
tome sections. Sectionswere stored at room temperature until
further processing.
2.6.2. Klu¨ver-Barrera Luxol Fast Blue Staining for Myelinated
Fibers. For evaluation of lesion pathology, 1 series of sections
from each animal was stained in Luxol Fast Blue (LFB) (0.1%
LFB in 95% ethanol (EtOH) and 0.05% acetic acid) at 60∘C
over night. Next day, sections were rinsed in 96% EtOH
and distilled H2O, immersed briefly in lithium carbonate
(0.05% Li2CO3 in distilled water), and differentiated in 70%
EtOH.Next, sections were rinsed thoroughly in distilledH2O
and immersed in 0.05% lithium carbonate to stop further
differentiation. Sections were then placed in hematoxylin,
rinsed in running tap water, and immersed briefly in eosin
solution. Finally, sections were rinsed in 70% EtOH, followed
by 3x 99% EtOH, placed in 3x xylene prior to mounting with
Depex. Prior to staining, paraffin embedded sections were
deparaffinized 3x 3min in xylene, 3x 2min in 99%EtOH, and
2x 2min in 96% EtOH.
2.6.3. Immunohistochemical Staining for CD45, F4/80, and
MBP. Heat-Induced Antigen Retrieval was done on paraffin
embedded sections by boiling the sections in citrate buffer
+ 0.05% Tween, pH 6.0 (MBP), Tris-EGTA buffer, pH 9.0
(CD45), or TRS buffer (Target Retrieval Solution, Dako)
(F4/80) first 15min at 900W and then 9min at 440W.
The sections were allowed to cool in the buffer before they
were blocked for endogenous peroxidase and biotin activity.
Sections were then incubated with anti-CD45 IgG (30-F11
(Ly 5); BD Pharmingen) diluted 1 : 100, anti-F4/80 IgG (AbD
Serotec) diluted 1 : 100, or anti-MBP IgG (Biolegend) diluted
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1 : 150 and detected using biotin-labeled anti-rat (Dako),
diluted 1 : 200, or anti-mouse, diluted 1 : 100, antibodies, fol-
lowed by ready-to-use anti-rabbit horse-radish perioxidase-
(HRP-) labeled polymer (EnVision+ System, Dako) with
diaminobenzidine (DAB) as chromogen (Dako). Nuclei were
counterstained using Mayer’s haemalum w/4.5% chloralhy-
drate. As negative controls, staining specificity was tested on
parallel sections of spinal cord tissue by omitting the primary
antibody or substitution with a primary antibody with a
similar concentration of amouse IgG1 isotype control (Dako)
(for MBP) in order to check for any unspecific reaction
from the detection system. As positive control for antibody
specificity, a mouse multiblock containing several different
tissues, including lymphatic organs, was included. Activation
patterns were investigated in 5 sections (representing 750𝜇m
spinal cord) centered on the lesion epicenter from each
animal.
2.6.4. Immunofluorescent Staining for Glial Fibrillary Acidic
Protein (GFAP) and Ionized Calcium Binding Adaptor
Molecule (Iba1). One series of sections from each animal
was deparaffinized and rehydrated by placing the sections 3x
3minutes in xylene, 3x 2minutes in 99% EtOH, 2x 2minutes
in 96% EtOH, 2 minutes in 70% EtOH, and finally 5 minutes
in running tap water. The sections were then demasked with
TEG-buffer by placing the sections in warm TEG-buffer in
a steamer for 15 minutes and then letting them cool for
15 minutes at room temperature before rinsing them for 15
minutes in running tap water. The sections were then rinsed
3x 15 minutes in Tris-buffered saline (TBS) before they were
preincubated with 10% fetal bovine serum (FBS) in TBS with
0.5% Triton X-100 for 30 minutes. Hereafter the sections
were incubatedwithAlexa Fluor 488-conjugated anti-GFAP
IgG (mouse monoclonal, clone 131-17719, Thermo Fischer
Scientific) diluted 1 : 400 or anti-Iba1 IgG (Rabbit, Dako)
diluted 1 : 400 1 hour at room temperature and hereafter over
night at 4∘C.
At day 2, sections were placed at room temperature for
30 minutes before they were rinsed in TBS for 10 minutes
and then in TBS with 0.1% Triton X-100 for 10 minutes.
Sections were then either stained with NeuroTrace 530/615
Red Fluorescent Nissl Stain (Thermo Fischer Scientific) for
20 minutes (GFAP) or incubated with Alexa Fluor 488-
conjugated chicken anti-rabbit IgG (Thermo Fischer Scien-
tific) 1 : 500 for 2 hours and then rinsed 2 × 10 minutes in TBS
before the nuclei were immersed in a TBS solution containing
10 𝜇Mdiamidino-2-phenylindole (DAPI) for 10 minutes.The
sections were shortly rinsed in distilled water before they
were mounted with ProLong Diamond. Activation patterns
were investigated in 5 sections (representing 750𝜇m spinal
cord) centered on the lesion epicenter from each animal.
Control reactions were performed by omitting the primary
antibody or by substituting the primary antibody with Alexa
Fluor 488 conjugated mouse IgG1kappa (Thermo Fischer
Scientific) or substituting the primary antibody with rabbit
serum (Dako) diluted to the same concentration as the
primary antibody. Sections were devoid of staining in the
FITC imaging filter.
2.7. Lesion Volume Estimation. The volume of the lesion was
determined from the area of every 10th LFB- orGFAP-stained
section sampled by systematic uniform random sampling.
The area of the lesion site was estimated in LFB-stained
sections as previously described [16] using the VisioMorph
software (Visiopharm) and the Cavalieri principle for volume
estimation. For estimation of the lesion area in GFAP-
stained sections, photomicrographs were acquired using an
Olympus BX51 microscope with an Olympus DP73 camera
connected to a PC set up with the Olympus CellSens soft-
ware. Lesion size was then estimated using ImageJ analysis
software (NIH) as per directions of the ImageJ developers
(http://rsb.info.nih.gov/ij/). Analysis performed on digital
images was carried out on unmanipulated pictures. On the
presented pictures the contrast and curves have been adjusted
to allow readers to appreciate the details on small-scale
figures.
2.8. Estimation of White Matter. The area of intact white
matter, based onMBP staining, was estimated as a percentage
of the total spinal cord tissue area. Estimations were based on
5 sections centered on the epicenter and 5 sections located
300 𝜇m rostral to the lesion (𝑛 = 10 sections from 2-
3 animals/group).
2.9. Flow Cytometry
2.9.1. Isolation of Cells for Flow Cytometry. Mice were per-
fused with PBS as described above, the spinal cords were
quickly removed, and tissue segments containing the lesion
area (2.5 cm centered on the lesion) and perilesion area
(0.5 cm distal to and 0.5 cm proximal to the lesion were
pooled to represent perilesion tissue) were placed in cold
Hank’s Buffered Salt Solution (HBSS). Tissue from individual
mice was processed separately. Single-cell suspensions were
obtained by homogenization in HBSS using 70-𝜇mnylon cell
strainers (BD Falcon). Cells suspensions were centrifuged at
300×g for 10 minutes at 4∘C. The pellet was resuspended
in PBS containing 0.5% FBS and Myelin Removal Beads
II (Miltenyi Biotec) were added and the suspensions were
incubated for 15 minutes at 4∘C. Thereafter PBS containing
0.5% FBS was added and the suspensions were centrifuged
at 300×g for 10 minutes at 4∘C, after which the pellet was
resuspended in PBS containing 0.5% FBS. The LS column
(Miltenyi Biotec) was placed in the magnetic field of the
MACS separator (Miltenyi Biotec) and columns prepared
by washing with PBS containing 0.5% FBS. Next, the cell
suspension was added and the flow-through was collected
and centrifuged at 300×g for 10minutes at 4∘C.Thepellet was
washed by resuspending in PBS and centrifuged at 300×g for
10 minutes at 4∘C. To lyse the red blood cells the pellet was
resuspended in 0.83% ammonium chloride for 10 minutes
after which the suspension was centrifuged at 300×g for 10
minutes at 4∘C.Thepellet waswashed by resuspending in PBS
and centrifuged at 300×g for 10 minutes at 4∘C. Finally the
pellet was resuspended in PBS and the cell suspension was
stained for live/dead cells using Fixable Viability Dye eFlouro
506 (eBioscience) for 20minutes at 4∘C in the dark.The pellet
waswashed by resuspending in PBS and centrifuged at 300×g
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for 10 minutes at 4∘C. Cells were fixed in Cytofix/Cytoperm
(BD Pharmingen) for 15 minutes at 4∘C and centrifuged at
300×g for 10 minutes at 4∘C. The pellet was washed twice
in FACS staining buffer (HBSS containing 2% FBS and 0.1%
sodium azide) and centrifuged at 300×g for 10 minutes at
4∘C in between. Finally the pellet was resuspended in FACS
staining buffer and kept in the dark at 4∘C until staining for
flow cytometry.
2.9.2. Flow Cytometry. The cells were blocked in 10% rat
serum for 30 minutes on ice before they were washed with
PBS and centrifuged at 600×g for 5 minutes at 4∘C. The
cells were resuspended in FACS staining buffer and stained
with combinations of PE-CD11b (BD Biosciences, clone
M1/70), PerCPCy5.5-CD45 (BD Biosciences, clone 30-F11),
APC-CD3 (BD Biosciences, clone 145-2C11), PE-Cy7-Gr1
(Biolegend, clone RB6-8C5), PE-Cy7-CD11c (BDBiosciences,
clone HL3), and 647-MHC class II (BD Biosciences, clone
M5/114.15.2) antibodies for 30minutes on ice. Finally, the cells
were washed in PBS, centrifuged at 600×g for 5 minutes at
4∘C, and resuspended in FACS buffer before they were run
on a FACSverse flow cytometer, and 106 events were acquired
per sample using forward scatter (FSC) and side scatter (SSC).
The analysis was performed using the FACSuite software [25].
Positive staining was determined based on the respective
isotype controls and the respective fluorescent minus one
(FMO) controls. The mean fluorescent intensity (MFI) was
calculated as the geometric mean of each population in the
CD45 and CD11b gates, respectively [25].
2.10. Multiplex and Western Blotting Analyses
Protein Purification. Whole spinal cord protein samples from
mTNFΔ/Δ and mTNFwt/wt mice exposed to SCI and allowed
3-day survival in addition to na¨ıve mTNFΔ/Δ and mTNFwt/wt
mice were obtained and protein extractions were prepared as
previously described [11, 12].
Multiplex Analysis. To measure cytokine, chemokine, and
TNFR protein levels by the MSDMouse Proinflammatory V-
Plex Plus Kit (IFN𝛾, IL-1𝛽, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12p70, CXCL1, and TNF; K15012C, Mesoscale) and mouse
TNF-RI, TNF-RII, RANTES, andMCP-1 Ultra-Sensitive Kits
(Mesoscale), we used a SECTOR Imager 6000 (Mesoscale
Discovery) Plate Reader according to the manufacturer’s
instructions. Samples were diluted twofold inDiluent 41 prior
to measurement and samples were run in duplicate [11]. Data
was analyzed using MSD Discovery Workbench software.
Western Blotting Analysis. Western blot analysis for Iba1
(1 : 500,Wako)was performedusing 18𝜇g protein extract sep-
arated on 4–12% SDS-PAGE gels (Invitrogen) using MOPS
SDS (Invitrogen) containing 0.25% antioxidant (Invitrogen)
essentially as previously described [11]. 𝛼-Actin (1 : 100,000,
Millipore) was used as loading control. SeeBlue prestained
standard (Invitrogen) was used as amolecular weightmarker.
Bands were quantified using Image Lab Software (Bio-Rad).
Analysis was performedwith 𝑛 = 4mice/group and data were
normalized to 𝛼-actin and presented as percentages relative
to mTNFwt/wt mice.
As a control, 2 independent gels were prepared where the
primary antibody was omitted in the protocol. Development
of the membrane showed the absence of a 17 kDa band,
corresponding to the size of Iba1.
2.11. Statistical Analysis. Comparisons were performed using
repeated measures (RM) two-way ANOVA followed by
multiple 𝑡-test analysis (BMS, rung walk, Hargreaves’ tests,
and weight change), Mann–Whitney, or Wilcoxon matched-
pairs signed rank tests. Analyses were performed using Prism
4.0b software for Macintosh (GraphPad Software). Statistical
significance was established for 𝑝 ≤ 0.05.
3. Results
3.1. Genetic Ablation of solTNF Does Not Alter Locomotor
Function or Anxiety-Related Behavior. Using the open field,
rotarod, and Y-maze tests, we previously demonstrated that
mTNFΔ/Δ mice display no obvious behavioral abnormalities
[12]. This was further validated in the present study using
the EPM test. We found that the time spent in the closed
(Figure 1(a)) and open arms (Figure 1(b)) and the total
distance travelled in the EPM were comparable between
mTNFwt/wt and mTNFΔ/Δ mice (Figure 1(c)). Together our
findings demonstrate that locomotor function following SCI
will not be affected by innate changes in the behavioral
phenotype between naı¨ve mTNFwt/wt and mTNFΔ/Δ mice.
3.2. Genetic Ablation of solTNF Does Not Affect Lesion Size or
Functional Outcome after SCI. On the basis of our previous
findings of a neuroprotective effect of mTNF [12, 16], we
investigated whether genetic ablation of solTNF in mTNFΔ/Δ
mice could also improve functional recovery and reduce tis-
sue damage following traumatic SCI. In this study,mTNFwt/wt
and mTNFΔ/Δ mice were subjected to SCI and locomotor
performance in the open field was recorded on days 1 and 3
and then weekly for 5 weeks and scored with the BMS. We
found that there were no differences in BMS scores between
the two genotypes at any time point after SCI (final BMS ±
SEM; mTNFwt/wt: 5.3 ± 1.0; mTNFΔ/Δ: 5.3 ± 1.5) (Figure 2(a)).
Both genotypes improved their BMS scores significantly over
time. Mice were also evaluated using rung walk analysis
when they reached a BMS score of 5 and weekly thereafter.
Even though both genotypes displayed significant changes
over time, no differences were observed between mTNFwt/wt
and mTNFΔ/Δ mice (Figure 2(b)). Thermal hyperalgesia was
tested using Hargreaves’ test. Despite findings of signifi-
cant changes in nociception over time in both mTNFwt/wt
and mTNFΔ/Δ mice, no difference between genotypes was
observed (Figure 2(c)). Finally in order to investigate the
effect of genetic ablation of solTNF on general activity and
anxiety-related behavior after SCI, mTNFwt/wt and mTNFΔ/Δ
mice were subjected to the open field test 35 days after SCI
(Supplemental Figure 1, Supplementary Material available
online at http://dx.doi.org/10.1155/2016/2684098). We found
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Figure 1: Elevated plus maze analysis in naı¨ve mTNFwt/wt and mTNFΔ/Δ mice. (a–c) mTNFwt/wt and mTNFΔ/Δ mice spent comparable times
in the closed arm (a) and the open arm (b) and travelled a similar distance (c) in the elevated plus maze test. Mann–Whitney test, 𝑛 = 7–
10mice/group. Results are presented as mean ± SD.
no differences in the total distance travelled (Supplemental
Figure 1A), in the speed at which the mice moved (Sup-
plemental Figure 1B), in number of rearings (Supplemental
Figure 1C), nor in number of zone changes (𝑝 < 0.05,
mTNFwt/wt: 45.0± 33.9;mTNFΔ/Δ: 37.5± 31.2), demonstrating
that mTNF is sufficient to sustain locomotor function. Also,
grooming (Supplemental Figure 1D) and urination (Sup-
plemental Figure 1E) and the center/perimeter ratio (𝑝 <
0.05, ratios: mTNFwt/wt: 0.08 ± 0.09%; mTNFΔ/Δ: 0.06% ±
0.10) were comparable between mTNFwt/wt and mTNFΔ/Δ
mice, and only the number of droppings differed significantly
between the two genotypes (Supplemental Figure 1F). In
line with these data, we observed no difference in lesion
size (Figures 2(d)–2(f)) or the percentage of MBP+ white
matter area (mTNFwt/wt: 48.6% ± 10.3%; mTNFΔ/Δ: 49.4% ±
12.0%) between mTNFwt/wt and mTNFΔ/Δ mice 35 days after
SCI. Intense GFAP immunoreactivity was detected both in
genotypes around the lesion and in the surrounding white
matter, indicating formation of a glial scar (Figure 2(g)).
Body weight was affected over time by SCI, but there was
no difference between genotypes (Supplemental Figure 1G).
3.3. Genetic Ablation of solTNF Reduces TNF Levels after SCI.
We previously showed that TNF is decreased in mTNFΔ/Δ
mice compared to mTNFwt/wt controls after experimental
stroke [12]. Following SCI, the genetic ablation of solTNF also
affected TNF in the spinal cord significantly (Figure 3(a)).
TNF increased significantly in mTNFwt/wt mice compared to
na¨ıve conditions and was significantly increased compared
to mTNFΔ/Δ mice 3 days after SCI, whereas TNF stayed at
baseline levels after SCI in mTNFΔ/Δ mice (Figure 3(a)).
TNFR1 (Figure 3(b)) and TNFR2 (Figure 3(c)) were also
significantly affected in the spinal cords of mTNFwt/wt and
mTNFΔ/Δ mice. We found that, in both mTNFwt/wt and
mTNFΔ/Δ mice, TNFR1 and TNFR2 increased significantly
in the lesioned spinal cord 3 days after SCI compared to
na¨ıve conditions but with no significant difference between
genotypes (Figures 3(b) and 3(c)). However, for both TNFR1
and TNFR2 there was a tendency towards reduced TNFR1
(𝑝 = 0.06) and TNFR2 (𝑝 = 0.06) levels in mTNFΔ/Δ
compared to mTNFwt/wt mice 3 days after SCI.
3.4. Genetic Ablation of mTNF Does Not Affect Neuroinflam-
mation in the Lesioned Spinal Cord 3 Days after SCI. IL-10
(Figure 3(d)), IL-1𝛽 (Figure 3(e)), and IL-6 (Figure 3(f)) were
significantly increased in mTNFwt/wt and mTNFΔ/Δ mice 3
days after SCI compared to na¨ıve conditions, but with no
significant difference between genotypes. However, there was
a tendency towards increased IL-10 (𝑝 = 0.09) and decreased
IL-1𝛽 (𝑝 = 0.09) in mTNFΔ/Δ compared mTNFwt/wt mice 3
days after SCI. IL-5 (Figure 3(g)) was significantly increased
at 3 days compared to na¨ıve conditions only in mTNFwt/wt
mice (Figure 3(h)), whereas IL-2 only increased significantly
in mTNFΔ/Δ mice (Figure 3(h)). IFN𝛾 and IL-4 protein levels
were not affected 3 days after SCI (not shown).
CXCL1 (Figure 3(i)) and CCL2 (Figure 3(j)) were signif-
icantly upregulated in the lesioned spinal cord of mTNFwt/wt
and mTNFΔ/Δ mice 3 days after SCI compared to naı¨ve
conditions, whereas the increase in CCL5 (Figure 3(k)) did
not reach statistical significance. No differences in CXCL1,
CCL2, and CCL5 were observed between mTNFwt/wt and
mTNFΔ/Δ mice (Figures 3(i)–3(k)).
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Figure 2: Genetic ablation of solTNF does not affect functional outcome or lesion size after SCI. (a) Analysis of BMS scores in mTNFwt/wt
and mTNFΔ/Δ mice showed that genetic ablation of solTNF did not affect BMS scores after SCI. Both groups of mice improved their BMS
score over time (two-way RM ANOVA; time ∗∗∗∗𝑝 < 0.0001, 𝐹3,133 = 295.1), 𝑛 = 10-11mice/group. (b) Rung walk analysis showed that
both groups of mice increased their number of mistakes after SCI (two-way RM ANOVA; time ∗∗∗∗𝑝 < 0.0001, 𝐹3,51 = 27.8, Tukey’s post
hoc ∗∗∗∗𝑝 < 0.0001), 𝑛 = 9-10mice/group, and no differences between genotypes were observed. (c) Thermal stimulation using Hargreaves’
test showed no differences in latency time to withdraw paws between genotypes. Both groups decreased latency to remove their paws over
time after SCI (two-wayRMANOVA; time ∗∗∗∗𝑝 < 0.0001, 𝐹3,51 = 14.72, Tukey’s post hoc ∗∗∗∗𝑝 < 0.0001), 𝑛 = 9-10mice/group. (d) Analysis
of lesion volumes in Luxol Fast Blue (LFB) stained sections 35 days after SCI showed that lesion size was comparable between mTNFwt/wt and
mTNFΔ/Δ mice (Mann–Whitney), 𝑛 = 5–9mice/group. (e) Representative LFB-stained thoracic spinal cord sections from mTNFwt/wt and
mTNFΔ/Δ mice allowed 35-day survival after SCI. Scale bar: 100𝜇m. (f) Analysis of lesion volumes in GFAP-stained sections 35 days after SCI
showed that lesion size was comparable between mTNFwt/wt and mTNFΔ/Δ mice (Mann–Whitney), 𝑛 = 5–9mice/group. (g) GFAP labeling
(green), fluorescent Nissl (red), and DAPI (blue) staining of representative spinal cord sections from mTNFwt/wt and mTNFΔ/Δ mice allowed
35-day survival after SCI. Results are presented as mean ± SD.
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Figure 3: Cytokine and TNFR expression profiling after SCI. (a–k) TNF (a), TNFR1 (b), TNFR2 (c), IL-10 (d), IL-1𝛽 (e), IL-6 (f), IL-5 (g), IL-2
(h), CXCL1 (i), CCL2 (j), and CCL5 (k) protein levels were quantified bymultiplex technology in naı¨vemice and 3 days after SCI inmTNFwt/wt
and mTNFΔ/Δ mice. For each protein, results are expressed as mean ± SD, 𝑛 = 5mice/group. ∗𝑝 < 0.05 and ∗∗𝑝 < 0.01, Mann–Whitney test.
3.5. Genetic Ablation of solTNF Does Not Affect Monocyte/
Macrophage Infiltration into the Lesioned Spinal Cord 3 Days
after SCI. We have previously shown that monocyte/macro-
phage infiltration into the ischemic brain is decreased
in mTNFΔ/Δ mice 24 hours after focal cerebral ischemia
compared to mTNFwt/wt mice [12]. Based on this, we
evaluated microglia (CD11b+CD45dim cells), macrophage
(CD11b+CD45highGr1−), granulocyte (CD11b+CD45highGr1+),
and T cell (CD45+CD3+) populations 3 days after SCI
using flow cytometry (Figures 4(a) and 4(b)) and found no
differences in total numbers (Figure 4(c)) and percentages
(Figure 4(d)) between mTNFwt/wt and mTNFΔ/Δ mice. As
CD45MFI values inmicroglia have been shown to be affected
by XPro1595 and etanercept treatment following experimen-
tal stroke, indicating increased activation by these cells [25],
we also investigatedCD11b andCD45MFI levels inmicroglia,
macrophages, and granulocytes 3 days after SCI (Figures 4(e)
and 4(f)). However, no difference between genotypes was
observed inMFI levels for eitherCD11b (Figure 4(e)) orCD45
(Figure 4(f)) in any of the cell populations investigated.
3.6. Genetic Ablation of solTNF Does Not Affect the Activation
State of Microglia and Leukocytes 3 and 35 Days after SCI.
In order to further investigate whether genetic ablation
of solTNF affected the activation state of microglia and
infiltrating cells, we performed flow cytometry and looked for
changes in cell populations and MFI of MHCII and CD11c
(Figure 5) in the lesion and perilesion areas (proximal and
distal to the lesion).The finding of comparable numbers (Fig-
ure 5(a)) and percentages (Figure 5(b)) of CD11b+CD45dim
microglia and CD11b+CD45high cells supported the finding
that solTNF does not affect microglial and leukocyte recruit-
ment following SCI. In order to investigate whether genetic
ablation of solTNF affected activation state, CD11b+CD45dim
and CD11b+CD45high populations were subgated to investi-
gate MHCII (Figures 5(d)–5(f)) and CD11c (Figures 5(g)–
5(i)) expression. Neither CD11c nor MHCII was found on
the microglia population at this time point (Figures 5(d)
and 5(g)). In contrast, MHCII (Figure 5(d)) and CD11c
(Figure 5(g)) expression were increased on CD11b+CD45high
cells with comparable numbers (Figures 5(e) and 5(h)) and
expression levels (Figures 5(f) and 5(i)) between genotypes.
The number of MHCII+ and CD11c+ cells and the expression
levels were significantly increased in the lesion area compared
to the perilesion area. CD11c were only found on MHCII
expressing CD11b+CD45high cells (Figure 5(j)). In support
of these data, the percentages of MHCII+, CD11c+, and
MHCII+CD11c+ cells in the lesion area were comparable
between genotypes (Figure 5(k)). Finally, Iba1 protein expres-
sion was investigated 3 days after SCI using Western blotting
analysis (Figure 5(l)). However, we found no difference in
the expression levels betweenmTNFwt/wt andmTNFΔ/Δmice
supporting the flow cytometric analysis, demonstrating that
genetic ablation of solTNF does not affect the activation state
of microglia and infiltrating cells 3 days after SCI.
We also evaluated microglia/macrophage activation 35
days after SCI by immunostaining of F4/80, CD45, and Iba1.
We observed no difference in the distribution or number
of F4/80+ (Figure 6(a)), CD45+ (Figure 6(b)), or Iba1+
(Figure 6(c)) cells between mTNFwt/wt and mTNFΔ/Δ mice.
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Figure 4: Flow cytometry of microglia and infiltrating leukocytes 3 days after SCI. (a) Gating strategy: FSC/SSC was used to define
cell populations. Singlet cells were identified using FSC-A/FSC-H, and only live cells were included. (b) Representative flow cytometry
plots comparing macrophage, granulocyte, and T cell infiltration in mTNFwt/wt and mTNFΔ/Δ mice. (c, d) Number (c) and percentage
(d) of microglia (CD11b+CD45dim), macrophages (CD11b+CD45dimGr1−), granulocytes (CD11b+CD45dimGr1+), and T cells (CD45+CD3+)
in mTNFwt/wt and mTNFΔ/Δ mice 3 days after SCI. Results are expressed as mean ± SD, 𝑛 = 5mice/group, Mann–Whitney test.
4. Discussion
In the present study, we found that genetic ablation of solTNF,
but sustained expression of mTNF, does not affect functional
outcome and lesion size after SCI. These findings are in line
with previous published papers demonstrating that genetic
ablation of TNF [15] and systemic administration of anti-TNF
antagonists, such as XPro1595 [16] and etanercept [16, 17], do
not affect lesion volume or improve functional outcome after
SCI. However, the findings are also in contrast to our own
recent studies demonstrating that selective central inhibition
of solTNF is neuroprotective, as mice treated epidurally
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Figure 5: Continued.
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Figure 5: Flow cytometric analysis of the activation state of microglia and infiltrating cells 3 days after SCI. (a–c) Number of CD11b+CD45dim
microglia (a) and CD11b+CD45high cells (b) and percentages of microglia and infiltrating cells (c) within the lesion and in the perilesion area
3 days after SCI. (d) Representative histograms of MHCII expression on CD11b+CD45low microglia and CD11b+CD45high cells located in the
lesions of mTNFwt/wt andmTNFΔ/Δmice 3 days after SCI. (e, f)The number ofMHCII+CD11b+CD45high cells (e) andMFI forMHCII (f) were
comparable between mTNFwt/wt and mTNFΔ/Δ mice. (g) Representative histograms of CD11c expression on microglia and infiltrating cells
located in the lesions of mTNFwt/wt and mTNFΔ/Δ mice 3 days after SCI. (h, i) The number of CD11c+CD11b+CD45high cells (h) and MFI for
CD11c expression (i) were comparable between mTNFwt/wt and mTNFΔ/Δ mice. (j) Representative dot blots comparing CD11c expressions on
MHCII+CD11b+CD45high cells in mTNFwt/wt and mTNFΔ/Δ mice 3 days after SCI. (k) Percentages of MHCII+, CD11c+, and MHCII+CD11c+
cells in the lesion area. 𝑛 = 4-5mice/group. (l)Western blot analysis for Iba1 protein expression 3 days after SCI.Data are normalized to𝛼-actin
protein expression (𝑛 = 4/group). Results are presented as mean ± SD, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, Mann–Whitney and Wilcoxon matched-pairs
signed rank tests.
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Figure 6: Microglial and leukocyte immunoreactivity 35 days after SCI. (a–c) Immunohistochemical staining for F4/80 (a) and CD45 (b)
and immunofluorescent staining for Iba1 (c) were comparable between mTNFwt/wt and mTNFΔ/Δ mice 35 days after SCI. Analysis was based
on 5 sections from each animal, 𝑛 = 4mice/group. Scale bars: (a, b) lowmagnification = 200 𝜇m and high magnification = 100 𝜇m. (c) 40 𝜇m.
with XPro1595 for 3 consecutive days displayed improved
functional outcome, reduced lesion size, and altered neu-
roinflammation after moderate SCI [16]. As TNF reaches
peak levels within the lesioned spinal cord within the first
1-2 hours after SCI [1–4] and elevation of solTNF is a
hallmark of acute neuroinflammation (reviewed in [26])
it is possible that, by inhibiting solTNF, using XPro1595
for only 3 consecutive days is neuroprotective, whereas
inhibiting solTNF for a sustained period of time (every 3
days for 35 days or as in TNF−/− and mTNFΔ/Δ mice) is not.
This is supported by recent hypotheses that under normal
physiological conditions solTNF signaling is important for
synaptic scaling (reviewed in [26]) and therefore possibly also
for neuroregeneration. In the present study, we observed a
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tendency towards reduced TNFR1 and TNFR2 expression in
the spinal cord ofmTNFΔ/Δmice 3 days after SCI, probably as
a consequence of reduced solTNF levels. As pharmacological
blockage of solTNF, using XPro1595 resulted in sustained
TNFR2 and increased TLR4 expression in the lesioned cord,
when administered epidurally [16], it is possible that, in order
to obtain improved functional recovery and reduced injury
following SCI, sustained or increased TNFR2 expression
locally is a prerequisite. This is supported by studies in mice
with experimental autoimmune encephalomyelitis (EAE), an
animal model of multiple sclerosis, where mTNF has been
associated with repair and remyelination via oligodendroglial
TNFR2 [27], whereas the detrimental effects of solTNF have
been associatedwith TNFR1 signaling [8, 28]. Finally, it is also
possible that genetic modifications of TNF expression, as in
TNF−/− andmTNFΔ/Δ mice, result in unknown phenotypical
modifications of the mice that may not be apparent at first
glance. Even though the behavioral phenotype did not appear
to be altered in mTNFΔ/Δ mice this is the case in TNF−/−
mice [29, 30] and discrepancies in study outcomes between
genetically modified TNF models and studies using anti-
TNF therapies have been encountered in other CNS models,
including models for focal cerebral ischemia and multiple
sclerosis (reviewed in [8, 31]). The explanation for these
discrepancies so far remains unknown and requires further
research into the different functional roles of solTNF and
mTNF and the importance of signaling through TNFR1
versus TNFR2.
We also observed a tendency towards a reduction in
CCL2 expression in mTNFΔ/Δ mice 3 days after SCI. CCL2 is
a monocyte chemotactic protein and an important regulator
of macrophage responses [32]. Its expression is upregulated
in rat spinal cord tissue within the first 24 hours after
SCI [33], as well as in serum samples from SCI patients
[34]. Despite our previous findings of a reduced infiltration
of monocytes/macrophages into the ischemic brain in our
mTNFΔ/Δ mice, we did not observe a difference in infiltrat-
ing macrophages 3 days after SCI between mTNFwt/wt and
mTNFΔ/Δ mice. We also did not observe any differences in
the activation state of microglia or infiltrating cells, as MFI
levels for CD11b, CD45, MHCII, and CD11c and Iba1 protein
expression were comparable between genotypes 3 days after
SCI. Macrophage infiltration and microglial activation are
known to peak around day 7 after SCI [35]; hence possible
changes in microglia/macrophages are believed to take place
at a later time after SCI, which may explain why we in the
present study did not observe any change in the number
of infiltrating macrophages. The finding that CXCL1, a neu-
trophil chemoattractant chemokine, did not differ between
mTNFwt/wt and mTNFΔ/Δ mice is in line with previous data
showing that neutrophils, which are known to infiltrate early
(peaking 1 day after injury) [35], were comparable between
mTNFwt/wt and mTNFΔ/Δ mice.
The expression of IL-1𝛽, a proinflammatory cytokine,
increases within the first couple of hours after SCI [4] before
the appearance of infiltrating lymphocytes and leukocytes
[36], and direct injection of IL-1𝛽 into the spinal cord
enhances vascular permeability and lymphocyte recruitment
[37]. In the present study, there was a tendency towards
reduced IL-1𝛽 expression in mTNFΔ/Δ mice 3 days after
SCI. In IL-1𝛼/𝛽−/− mice, locomotor activity and lesion area
improved significantly after SCI, a process believed to be
mediated by reduction of inflammatory responses, including
a decrease in TNF expression [38].We have previously shown
that IL-1𝛽 protein levels are decreased in mTNFΔ/Δ mice
following experimental stroke, which was accompanied by
reduced infarct volumes [12], and that, by increasing the
expression of the naturally occurring IL-1 receptor antagonist
(IL-1ra) in microglia, infarct volumes following experimental
stroke can be reduced [39]. As the neurotoxic effect of IL-
1𝛽, and hence its deleterious effect on lesion volume, is
dependent on the balance between IL-1 and IL-1ra after acute
injury to the CNS [39], it is possible that in our conditions
a sufficient increase in IL-1ra does not occur, and therefore
the decrease in IL-1𝛽 expression in our mTNFΔ/Δ mice is not
sufficient to improve functional recovery and reduce lesion
size.
IL-10 is a potent anti-inflammatory cytokine, which has
been shown to reduce the development of inflammation and
tissue injury associated with SCI [40]. IL-10 has also been
shown to reduce IL-1𝛽 [41] andTNF [42] in ratmodels of SCI,
leading to reduced inflammation, reduced neuronal damage,
and improved functional recovery. In our study, we observed
a tendency towards reduced IL-10 levels, while TNF and IL-1𝛽
were decreased, with no improvement in functional outcome
35 days after SCI. As the studies performed by Bethea et
al. [42] and Plunkett et al. [41] were in rats and ours was
in mice, it is possible that species differences account for
the discrepancy. Our studies are in line with the findings
by Abraham et al. [43] that showed greater damage at early
time points (1 and 7 days) after SCI in IL-10−/− mice but no
differences at 14 days after SCI.The pronounced early damage
observed in IL-10−/− mice was associated with an almost
twofold increase in peripheral neutrophils [43], suggesting
an altered innate immune response to injury. Despite the
findings of increased IL-10 3 days after SCI, we did not see
any difference in infiltrating macrophages and neutrophils.
At 35 days after SCI we did not detect differences in CD45+,
F4/80+, or Iba1+ microglia/macrophages. However, it should
be noted that these observations were based on qualita-
tive immunohistochemistry and further quantitative analysis
should be performed in order to conclude whether leukocyte
infiltration is affected by genetic ablation of solTNF following
SCI.
In summary, our study, using genetically modified mice
expressing only the membrane-bound form of TNF, demon-
strate that the absence of solTNF does not affect lesion size
and functional outcome but suggests that mTNF promotes an
anti-inflammatory environment in the lesioned spinal cord
that may be more favorable to functional recovery.
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